360 results on '"Postel Vinay S"'
Search Results
2. Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022
3. Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours
4. Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors
5. Epigenetic modifiers as new immunomodulatory therapies in solid tumours
6. ANTIBODY DRUG CONJUGATES IN OLDER PATIENTS: STATE OF THE ART
7. Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey
8. Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism
9. 30P OSE279, a PD-1-blocking monoclonal antibody, as future backbone of a bifunctional checkpoint inhibitor platform: Preliminary results of a first-in-human (FIH) study in subjects with advanced malignancies
10. Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape
11. Immune-related adverse events with immune checkpoint blockade: a comprehensive review
12. Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies
13. Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?
14. 41P BRCA2 pathogenic variant (PV): A novel agnostic biomarker for immune checkpoint blockers (ICB)?
15. 86P Validation of the Gustave Roussy Immune (GRIm) score in patients treated with bispecific CD3 T cell engagers in phase I clinical trials
16. 109O Phase I study of MEDI9253, a recombinant Newcastle Disease Virus encoding interleukin-12, in combination with durvalumab in participants with select advanced/metastatic solid tumors
17. Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): A European survey conducted by the European Society for Medical Oncology (ESMO) Young Oncologists Committee
18. 456MO METEOR-1: A phase I study of the safety and efficacy of the protein arginine methyltransferase 5 (PRMT5) inhibitor GSK3326595 in advanced solid tumors
19. 1742P Phase II study of rucaparib and atezolizumab (ARIANES): Results in patients (pts) with platinum-sensitive metastatic urothelial cancer (mUC) and metastatic castration-resistant prostate cancer (mCRPC)
20. 461P Overview of patients inclusions and outcomes into modern phase I trials at Gustave Roussy over the last 5 years, OVATION study
21. EP08.02-116 Design of a Phase 1 Study of AMG 193, an MTA-Cooperative PRMT5 Inhibitor, in Patients with Advanced MTAP-Null Solid Tumors
22. 1672P Tumor and immune cell dynamics at single-cell resolution on combined PARP inhibition and anti-PD-L1 therapy
23. 508P High prevalence of clonal hematopoiesis of indeterminate potential (CHIP) associated mutations in elderly patients with solid tumors
24. 657P Prospective validation of the T cell engager (TCE) score in patients treated with bispecific CD3 TCE antibodies in phase I clinical trials
25. 604O Phase I dose escalation and initial dose expansion results of AMG 193: A MTA-cooperative PRMT5 inhibitor, in patients (pts) with MTAP-deleted solid tumors
26. 469P Detection of circulating tumor DNA (ctDNA) in cerebrospinal fluid (CSF) in patients with glioblastoma treated in phase I clinical trial
27. Méthodes pour la recherche de dose de traitements ciblés : nouvelles pistes
28. A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer
29. 1452P Use of the Pallia 10 score in patients enrolled in phase I trials at Gustave Roussy Cancer Center
30. 1617P Sustained cancer clinical trial activity during the COVID-19 pandemic
31. Phase I trials in oncology: a new era has started
32. Olaparib maintenance vs placebo in platinum-sensitive non-small cell lung cancer: The phase II randomized PIPSeN trial
33. 821TiP Phase I study of ceralasertib (cerala) in combination with AZD5305 in patients (pts) with advanced/metastatic ovarian cancer (OC) previously treated with PARP inhibitors (PARPis)
34. 654O Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): Primary results from the international phase II DESTINY-PanTumor01 (DPT-01) study
35. 2158P A self-assessment survey to identify the risk of patient’s screen fail in phase I clinical trials (SCITEP trial)
36. 3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer.
37. Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study
38. 100MO Olaparib maintenance vs placebo in platinum-sensitive non-small cell lung cancer: The phase II randomized PIPSeN trial
39. 22P Toxicity profile of immune and non-immune therapies in phase I/II trials: A comprehensive longitudinal analysis
40. 9P Predictive factors and profiles of tumour response to epigenetic drugs in phase I trials
41. Tumour markers fluctuations in patients with medullary thyroid carcinoma receiving long-term RET inhibitor therapy: ordinary lapping or alarming waves foreshadowing disease progression?
42. Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor
43. 47P Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugs
44. SP-0258: Potentiation of anti-tumor immune effects by PARP Inhibitors
45. 1930O Genomic alterations in solid tumours according to ESMO scale for clinical actionability of molecular targets (ESCAT)
46. 472P Prognostic markers in patients (pts) with solid tumors submitted to bispecific T-cell engagers in phase I (phI) clinical trials
47. Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)
48. Comparison of molecular profiles between primary tumour and matched metastasis in non-small cell lung cancer
49. Precision medicine for patients with primary brain tumours: Molecular screening for cancer treatment optimization (MOSCATO) prospective trial
50. Abstract OT3-05-03: MEDIOLA: An open-label, phase I/II basket study of olaparib (PARP inhibitor) and durvalumab (anti-PD-L1 antibody)–Additional breast cancer cohorts
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.